4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0000899243-18-001348
Chief Legal Officer sold 66,000 shares at an average $28.03 ($1,850,255)
- Chief Legal Officer acquired 21,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Dylan-Hyde Tyler Chief Legal Officer | 2018-01-16 | Sale | −45,000 | $28.00 | $1,260,000 | 25,204 | D |
| Dylan-Hyde Tyler Chief Legal Officer | 2018-01-16 | Option exercise | +1,110 | $12.57 | $13,953 | 26,314 | D |
| Dylan-Hyde Tyler Chief Legal Officer | 2018-01-16 | Sale | −1,110 | $28.24 | $31,346 | 25,204 | D |
| Dylan-Hyde Tyler Chief Legal Officer | 2018-01-16 | Option exercise | +19,890 | $12.57 | $250,017 | 45,094 | D |
| Dylan-Hyde Tyler Chief Legal Officer | 2018-01-16 | Sale | −19,890 | $28.10 | $558,909 | 25,204 | D |
| Derivatives | |||||||
| Dylan-Hyde Tyler Chief Legal Officer | 2018-01-16 | Option exercise · Stock Option (Right to Buy) | −1,110 | 36,663 | D | ||
| Dylan-Hyde Tyler Chief Legal Officer | 2018-01-16 | Option exercise · Stock Option (Right to Buy) | −19,890 | 5,237 | D | ||
| Open-market sales · 66,000 sh · avg $28.03 · $1,850,255 | |||||||
Loading xslF345X03/doc4.xml…